DERAZANTINIB
Derazantinib is a selective FGFR inhibitor that blocks aberrant FGFR signaling in cancers such as cholangiocarcinoma. Benefits include tumor growth suppression and targeted therapy potential. Side effects include fatigue, hyperphosphatemia, dry mouth, and liver enzyme elevation due to FGFR pathway modulation. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
Derazantinib (ARQ 087) is a selective panFGFR inhibitor targeting FGFR13. It blocks ATP binding at the tyrosine kinase domain, suppressing downstream MAPK, PI3K/AKT and STAT signalling. It is particularly active in tumours with FGFR2 fusions, amplifications or activating mutations.
Benefits and Advantages
Used in FGFRdriven tumour models, kinaseinhibitor SAR studies, receptortyrosinekinase pathway research, drugresistance mechanism analysis, and precisiononcology investigations.
Side Effects and Risks
Risks include hyperphosphatemia, fatigue, GI toxicity, ocular disturbances, hepatotoxicity and nail changes. Handle with targetedkinaseinhibitor containment.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C29H29FN4O |
|---|---|
| Molecular Weight | 468.6 g/mol |
| CAS Number | 1234356-69-4 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Derazantinib; 1234356-69-4; ARQ-087; ARQ087; ARQ 087 |
| IUPAC/Chemical Name | (6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine |
| InChl Key | KPJDVVCDVBFRMU-AREMUKBSSA-N |
| InChl Code | InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
